Cardiac and Renal Fibrosis in Chronic Cardiorenal Syndromes

被引:36
|
作者
Hundae, Aneley [1 ]
McCullough, Peter A. [1 ,2 ]
机构
[1] Baylor Univ, Med Ctr, Baylor Heart & Vasc Inst, Baylor Jack & Jane Hamilton Heart & Vasc Hosp, Dallas, TX USA
[2] Heart Hosp, Plano, TX USA
来源
NEPHRON CLINICAL PRACTICE | 2014年 / 127卷 / 1-4期
关键词
11TH CONSENSUS CONFERENCE; HEART-FAILURE; GALECTIN-3; PATHOPHYSIOLOGY; MANAGEMENT; ST2; MARKER;
D O I
10.1159/000363705
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
In recent years, there has been considerable interest in cellular and tissue responses to injury that result in the deposition of extracellular matrix, collagen, elastic fibers, and the histopathological development of fibrosis. In the myocardium, fibrosis results in many recognizable clinical features, including PR interval prolongation, heart block, bundle branch block, left ventricular dyssynergy, anisotropy, atrial fibrillation, ventricular arrhythmias, systolic and diastolic dysfunction, heart failure, and cardiac death. In the kidneys, fibrosis in the glomerulus leads to glomerular sclerosis, and in the inner cortex and medulla, tubulointerstitial fibrosis leads to a reduction in renal filtration function and rapidly progressive chronic kidney disease. There are a great number of potential early mediators of cellular damage in response to events such as ischemia, neurohormonal activation, biomechanical stretch, and abnormal cell signaling. However, many studies suggest that interstitial cells in both organs, including macrophages, T lymphocytes, fibroblasts, and myofibroblasts, have common communication systems that utilize galectin-3 and transforming growth factor-beta that result in the upregulation and proliferation of fibroblasts and myofibroblasts, which produce and secrete procollagen I. Procollagen I cross-links in the extracellular space to form mature collagen, which is a fundamental unit of organ fibrosis. Future research will be concentrating on the pathogenic mechanisms that turn on fibrosis and on therapeutic targets that can either prevent the activation of fibroblasts or limit their repair response to injury. (C) 2014 S. Karger AG, Basel
引用
收藏
页码:106 / 112
页数:7
相关论文
共 50 条
  • [21] Valsartan attenuates cardiac and renal hypertrophy in rats with experimental cardiorenal syndrome possibly through down-regulating galectin-3 signaling
    Zhang, M. -J.
    Gu, Y.
    Wang, H.
    Zhu, P. -F.
    Liu, X. -Y.
    Wu, J.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (02) : 345 - 354
  • [22] Prevalent cardiac, renal and cardiorenal damage in patients with advanced abdominal aortic aneurysms
    Barisione, Chiara
    Garibaldi, Silvano
    Brunelli, Claudio
    Balbi, Manrico
    Spallarossa, Paolo
    Canepa, Marco
    Ameri, Pietro
    Viazzi, Francesca
    Verzola, Daniela
    Lorenzoni, Alessandra
    Baldassini, Riccardo
    Palombo, Domenico
    Pane, Bianca
    Spinella, Giovanni
    Ghigliotti, Giorgio
    INTERNAL AND EMERGENCY MEDICINE, 2016, 11 (02) : 205 - 212
  • [23] Attenuation of Circulating Trimethylamine N-Oxide Prevents the Progression of Cardiac and Renal Dysfunction in a Rat Model of Chronic Cardiorenal Syndrome
    Zou, Deling
    Li, Yanyu
    Sun, Guangping
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [24] Atherosclerotic renal artery stenosis is prevalent in cardiorenal patients but not associated with left ventricular function and myocardial fibrosis as assessed by cardiac magnetic resonance imaging
    Emans, Mireille E.
    van der Putten, Karien
    Velthuis, Birgitta K.
    de Vries, Jan J. J.
    Cramer, Maarten J.
    America, Yves G. C. J.
    Hillege, Hans L.
    Meiss, Louis
    Doevendans, Pieter A. F. M.
    Braam, Branko
    Gaillard, Carlo A. J. M.
    BMC CARDIOVASCULAR DISORDERS, 2012, 12
  • [25] Novel Renal Biomarkers to Assess Cardiorenal Syndrome
    Brisco M.A.
    Testani J.M.
    Current Heart Failure Reports, 2014, 11 (4) : 485 - 499
  • [26] Therapeutic Strategies for Heart Failure in Cardiorenal Syndromes
    House, Andrew A.
    Haapio, Mikko
    Lassus, Johan
    Bellomo, Rinaldo
    Ronco, Claudio
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 56 (04) : 759 - 773
  • [27] Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers
    Rezk, Tamer
    Lachmann, Helen J.
    Fontana, Marianna
    Naharro, Ana Martinez
    Sachchithanantham, Sajitha
    Mahmood, Shameem
    Petrie, Aviva
    Whelan, Carol J.
    Pinney, Jennifer H.
    Foard, Darren
    Lane, Thirusha
    Youngstein, Taryn
    Wechalekar, Ashutosh D.
    Hawkins, Philip N.
    Gillmore, Julian D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (03) : 460 - 470
  • [28] Cardiac fibrosis
    Samuel, Jane-Lise
    Delcayre, Claude
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2017, 201 (4-6): : 775 - 784
  • [29] Epidemiology and Natural History of the Cardiorenal Syndromes in a Cohort with Echocardiography
    Mavrakanas, Thomas A.
    Khattak, Aisha
    Singh, Karandeep
    Charytan, David M.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (10): : 1624 - 1633
  • [30] Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndrome
    Lekawanvijit, Suree
    Kompa, Andrew R.
    Zhang, Yuan
    Wang, Bing H.
    Kelly, Darren J.
    Krum, Henry
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2012, 302 (09): : H1884 - H1893